This ad first showed up in our inboxes under the “end surgery forever” headline in late January, and the following article first appeaered on January 26.
We have not gone through and updated the article, though the basic pitch is just about the same in the new version of the ad today as it was then. The “Major Announcement” is getting a bit closer, because the Company has consistently said they expect to hear a response from the FDA in the first quarter (and that ends on March 31).
Whether or not this widely-expected response from the FDA will have an immediate positive impact on the shares, I don’t know. The odds of approval seem quite high, I have not seen any analysts predict that they’ll fail to get approval this time … though there was also a sharply worded short attack on the shares from TheStreetSweeper a couple weeks ago. You can read the comments following the article for some of those updates and reactions along the way, but the rest of this article is unchanged from when it first appeared here six weeks ago:
“Intuitive Surgical’s stock price bolted from $3 all the way to $561 a share today.
“That’s a 19,000% return…
“Good enough to turn $10,000 into $1.9 million…
“And yet, it’s just a glimpse of the gains coming down the pike right now.
“You see, as innovative and groundbreaking as da Vinci is…
“Keep in mind, it’s not perfect.
“And the $2 company I’m recommending today has the patented technology to take robotic surgery to the next level…”
That’s what caught some of our readers’ eyes from a recent Ernie Tremblay ad — he’s looking for new subscribers to his Biotech Insider Alert, and in order to entice you he’s hinting about the “next Intuitive Surgical.”
That’s like waving a sausage in front of a dog, we can’t help but keep following — every investor is enchanted with the idea of finding the next mega-growth stock like Intuitive Surgical (ISRG) and their da Vinci machine. Even those of us dummies who sold the stock $400 ago (don’t ask).
So what’s this new technology? More from Tremblay:
“Their new technology isn’t just a tool used by a surgeon…
“It merges with the surgeon…
“Creating a whole new reality. Part man. Part machine.
“In short, a ‘bionic surgeon.'”
Cue the obligatory references to the Six Million Dollar Man (or, inflation adjusted, the $22 Million Man), but what Tremblay is touting here is a company with some sort of next-level surgical robot system, an improvement over Intuitive Surgica’s da Vinci.
More clues:
“… it’s moved through the FDA approval process while attracting some of the savviest technology investors on the planet, including a billionaire often referred to as the ‘Warren Buffet of biotech….’
“… you need to understand that in the coming weeks, this breakthrough bionic surgeon could hit every hospital and surgical center on the planet.”
“In the coming weeks?” Be serious. Even if this weren’t a half-million-dollar machine it would take time to roll out and build to critical scale.
"reveal" emails? If not,
just click here...
Some of the biotech-savvy among you have already guessed what stock this is, I imagine, but don’t ruin the surprise for everyone else…
let’s check out some more clues:
“Surgeons ‘wear’ the technology and are always in the same room conducting the surgery themselves.
“If there’s a problem, the surgeon is right there next to the patient – inside the sterile field – able to respond immediately.
“This is crucial. One surgeon puts it this way:
‘If you’re sitting on a console 10 feet away, you’re not scrubbed in. If there’s catastrophe on the field the first thing you have to do is: somebody has to undock the unit… Then you have to move the entire apparatus off the field while you run outside and scrub. If you think about the amount of time it takes to do that, it might be a few minutes, but it’s a lifetime literally to that patient.’
“Problems like these won’t happen with this new technology.”
I don’t know that this is a particularly big problem with the da Vinci, it’s not like the patient is alone in the room with the machine while the doctor’s across campus. But that’s beside the point, more clues:
“…. the Bionic Robot gives surgeons an intimate feel for what they are doing….
“It’s almost like they are wearing bionic surgical gloves.
“They can actually ‘feel’ what they are doing, adding human sensibilities that a robot alone could never deliver.
“Here’s how Dr. Juan-Carlos Verdeja – Director of Surgery at Baptist Health – describes this game-changing benefit…
‘It has the opportunity to revolutionize the robotic market. The platform allows me to scrub in and work at the patient’s side, and maintains a tactile feel that I want as a surgeon.'”
That has been a complaint, sometimes, about Intuitive Surgical — their robot doesn’t have the “haptic” touch feedback that surgeons would prefer.
And yes, this is another kind of laparoscopic surgery — minimally invasive, like conventional laparoscopy or the da Vinci, the tools and camera go through a small incision (or incisions) and the surgeon performs his (or her) maneuvers under the skin. More from the ad:
“The surgeon makes a small, single incision – often hidden in the patient’s belly button.
“He then inserts a small tube which opens up like an umbrella, delicately positioning tiny surgical instruments inside the patient.
“The surgeon controls the instruments with his hands, all the while watching through a ‘bionic eye’ via a high definition camera.”
And more on that cost differential Tremblay noted:
“Intuitive Surgical’s da Vinci robot is priced as high as $2 million, putting it out of reach for most hospitals.
“You might expect this next-generation Bionic Surgeon to be even more expensive…
“I mean, it’s such a drastic improvement, a higher price – even as high as $3.5 million or more – would be justified.
“But it’s not more expensive…
“In fact, this tiny $2 company’s breakthrough Bionic Surgeon is 75% LESS than Intuitive Surgical’s da Vinci robot.
“That’s right. While the da Vinci robot can cost $2 million, the Bionic Surgeon will only cost around $500,000.”
Who is it? Here they’re teasing TransEnterix (TRXC), which is a very small company ($180 million market cap, looks like they have plenty of cash) that’s been acquiring other small robotic technology companies in recent years and developing what is, to some extent, a da Vinci competitor.
The machine Tremblay’s mostly referring to is the SurgiBot, which is a smaller, one-port laparoscopy machine, but they also did recently acquire the Italian company behind the Alf-X, which is a multi-port laparoscopy robot that seems more similar to the big da Vinci. The SurgiBot is currently with the FDA for review and TransEnterix expects clearance within the next few months (the general expectation is 6-9 months from submission, and they submitted the application for approval in June).
And our own Dr. KSS went into quite a bit of detail on TransEnterix over the Summer, so I’ll just let you go over and read his article for more background (the stock ha also been discussed pretty widely in the discussion sections of Dr. KSS’s other articles). I don’t have an opinion on this one, though the space seems more competitive now than it was when Intuitive Surgical was getting started — but I wanted to get this teaser solution out to you quickly instead of spending a few hours looking at the stock, but it has sure come down in price in these weeks leading up to possible (likely, most folks seem to think) approval.
When you buy stocks in the middle of a major bear market you are most likely to get burned. Now is the time to eschew any and all buy recommendations until the bear is finished. Yes, I know there are always a tiny percentage of stocks that up during a bear market. And a particular sector might end its downtrend earlier than the rest. But right now we’ve a long way to go before it’s over.
It’s true that stocks have been going down, but saying that we’re in the “middle of a major bear market” is making a forecast. I don’t know if it will end in a month or a year or whenever, or if it’s a correction and the bull market will surge higher next week. It sure feels like a bear market, most stocks are in a downtrend, and I’d be surprised if the market surged higher, but feeling isn’t everything. Not that I think folks should rush out and buy this stock, or any stock, but I try to find some sanity in thinking about individual businesses and letting the much-less-predictable broad market do its own thing.
I played this a little differently. On Feb 8 I bought 3000 shares of TRXC at 3.55 and sold the April 15 2.50 options for 1.60 for an entry cost of 1.92. If TRXC closes above 2.50 on April 15 I will net .55 for a 28% gain or annualized 153%. I’m nervous about the market and about a much hyped stock and this is a conservative way to get in on some gains. Admittedly, if the stock really takes off, I can’t make more than the 28% and I could lose if TRXC closes below 1.92 on April 15 , but I would probably buy back the option if the stock really tanks and sell the stock. The setup is not quite as lucrative now as it was on Feb 8 but a nice return can still be had with this trade.
We are in a perma bear market…
iI use a complex chart to determine if a market crash is immenient.
It’s called the How does my indicator work to perfectly predict stock market crashes 100% of the time? I utilizes the BofA Merrill Lynch US High Yield Master II Option-Adjusted Spread (OAS), which is the calculated spread between an index of all corporate junk bonds (rated BB or below) and US Treasuries. I created a chart of the High Yield/Junk Bond OAS and added the S&P 500 to the opposite axis.
Normally, when the S&P 500 rises, the junk bond spread simultaneously declines. To make it easier to compare their latest trends, I inverted the High Yield/Junk Bond OAS chart. If the S&P 500 is rising and the junk bond spread is simultaneously tightening like it’s supposed to – both the S&P 500 chart and the High Yield/Junk Bond OAS chart will rise together. If the S&P 500 is declining and the junk bond spread is simultaneously widening like it’s supposed to – both the S&P 500 chart and the High Yield/Junk Bond OAS chart will fall together.
The’s indicator then calculates the trailing 12 month correlation between the S&P 500 and High Yield/Junk Bond OAS. During normal healthy economic/market conditions of the S&P 500 rising alongside tightening junk bond spreads and declining alongside widening junk bond spreads – the correlation between the two will be very negative. Since 1997, the correlation has averaged -75.07% and has been in negative territory 86.1% of the time.
Very rarely do these two trends diverge from each other. When the S&P 500 bottomed during the financial crisis in March 2009 at 676.53, the junk bond spread at the time was 18.86%. For the following 63 consecutive months, the S&P 500 trended upward as junk bond spreads trended downward – averaging an unbelievably strong negative correlation during this time period of -90%. In June 2014, the High Yield/Junk Bond OAS hit a new 7-year low of 3.35%, with the S&P 500 simultaneously reaching 1,963 up 190% from its bottom.
During the 12 months since then, the S&P 500 has continued soaring to record highs, but extremely concerning is its divergence with the High Yield/Junk Bond OAS that has occurred since then. As the S&P 500 continued rising to new record highs, the High Yield/Junk Bond OAS should have continued declining back to its record low set in 2007 of 2.41%. Instead, as the S&P 500 gained 6.52% to a new record high in December 2014 of 2,091, junk bond spreads simultaneously increased as much as 236 basis points to 5.71%. This caused their correlation to soar from an incredibly strong June 2014 low of -97.5%, to a positive year-end 2014 correlation of 40.81%, its first positive correlation in 7 years.
Their recent divergence is extremely similar to what occurred in mid-2007 when the S&P 500 reached its pre-financial crisis peak. After the High Yield/Junk Bond OAS set a record low in June 2007 of 2.41%, junk bond spreads increased as much as 238 basis points to 4.79% within the following three months – as the S&P 500 continued rising to new record highs. This caused their correlation to become positive for the first time in 7 years, signaling with the S&P 500 trading at 1,520.27 that a crash was coming. The S&P 500 declined 55.5% over the following 16 months.
In 2000, their correlation becoming positive marked the very top of the dot-com bubble, right before a two-year decline of 47.55%.
The 2015 divergence has been much more dramatic than in 2000 and 2007 – with their correlation reaching 60.07%, which is the most positive it has been in 17 years. This is a strong indicator that the upcoming crash could be far more devastating than the previous two.However other events can occur, meaning it will happen in less time or may take more time.Stay tuned.
Reference chart below….BofA Merryll Lynch US High Yield Master II Option-Adjusted Spread (OAS) vs. S&P 500 and Trailing 12 Month Correlation
SEE->http://inflation.us/perfect-predictor-of-crashes/
Huh?
mshtexas, I’ll double that “Huh”, and see you with a “Duh” to comment above LOL
PS TRXC. is in my opinion a rock solid “Once in a life time play” I’ve been doing D&D on this co. for about 3 weeks now ever since coming over here and having Travis decode the annoying emails I was getting from Ernie. Have to tell you I can’t find a darn thing wrong with it. They went and built a better mouse trap that really will not compete with Da Vinci That much. Their other platform ALF-X may compete a little more in that area, but has features like haptic feedback, and eye tracking software that Da Vinci does not have.
Their management team are “Al stars” 2 new Hires for sales just came over from Intuitive.
They are getting great feedback from surgeons, Surgibot is cheap as heck at 500K which starts making the cost per procedure very affordable. That is the bottom line to hospitals and insurance companies.
Do your own D&D, but the FDA is supposed to give them the green light Mid-April, and there should be no problems. Once they get it I doubt shares will be in the 4 dollar range for long.
Thanks Travis for your wonderful service. 🙂
Steve
The Old World Order is being rolled up. And the New World Order is being rolled out in its place.
Yes, one should always ignore items on sale at a good price and wait until the price rises.
Depressed by this market? I am exhilarated!
When there’s blood in the street. That’s when you buy and hold. Because you are buying at depressed prices, providing you buy the right stock for the right reasons. Buffet usually buys 25% in a company, gets to know the management, gains inside information that is not public knowledge, then: just like Icahn bought Netflix: got inside information, got a board seat, pushed the company higher when it was a 500 stock and all the hedge funds followed him into that stock; then he got out after making billions and now Netflix is barely 100. I believe that’s the way they gain inside information, then they decide like Warren whether to buy the whole company. Buffet, Icahn, Bill Ackman will buy and hold or take it private in a bull or a bear market. I’m the same way. I’ll buy a stock and hold it if I believe in it!!
Netflix had a 7-1 stock split last year – that’s why it’s in the $100/sh range now.
Mike You are correct. Many companies like to keep the price of their stock at not much over $100.00 Part of the reason is that options are traded in blocks of 100 shares,
and where someone might lay out $10,000.00 for a trade they might be hesitant to place $70,000.00 at risk for a trade that may only return a few hundred$$$.
That $2 stock is now a $4 stock and those who bought early have already doubled, despite your bearish outlook.
How do you know? .. What is the stock code of the $2 stock that is now a $4 stock? .. I’d like to check into it more. – Thanks!
Norma, It’s TRXC
FDA Decision y the end of March. I’m in at about 3.75 and long
sjanus11, ditto for me on both counts
Uncle Albert, I’ve spent 2 weeks doing D&D and this Co. and for the life of me I’ve come to the conclusion it is a “Once in a life time” opportunity.
FDA approval could come anytime this week. It should go thru as one of the team has 9 yrs experience working FDA doing just that. Examining the 501k’s for approval.
FDA would love comp in market. There management team is stellar.
2 new platforms with “Haptic” which Da Vinci does not have. Market at about 2 Billion now, and projected to go to around 10 Billion in around 4-5 yrs. Heck even if they just capture
5% of that? It’s mind boggling. Here’s a great link on what the company could do.
http://www.thewallstreetfox.com/2015/03/transenterix-how-big-can-it-become_31.html
Also the pricing on Surgibot is like 500k compared to around 2 mil for Da Vinci.
The tooling will bring in great revs to. Now all they have to do is sell the damn things. LOL
From what I’ve read the reception for product has been great. Time will tell how well they execute the sales end. Lot’s of instatutional backing and insiders buying. They must agree with sales plan.
I’m thinking “generational” wealth creation here. Or pie in the sky. LOL
A guy can dream can’t he.
PS can’t wait for the short squeeze… hehehhehe
On 3/07/2016, I bought 2000 shares of TRXC at $4.09…missed the run-up to $5.00 but saw the the most recent activity and put in a sell order lat week at $4.90 which would be 20% gain which was executed this week…had been severely underwater with this stock for the past two years so was ecstatic to get out with a 20% gain…have told my wife that it is not a loss until I sell it
Think that the stock may have been CPXX, up almost 400% today on Leukemia drug news
Certainly has been a huge performer on that news, but it hasn’t been aggressively teased by a newsletter — at least, not that I’ve seen over the past year. It has been discussed quite a bit in the biotech threads.
Definitely not the stock being pitched as this “end of surgery” or “bionic surgeon” — that’s clearly TransEnterix, which continues to await word from the FDA. As far as I can tell, investors have high expectations about FDA approval so it would be pretty surprising if TRXC moved nearly as dramatically if the FDA approves their SurgiBot as CPXX did today on its news.
$CPXX-MM, not a chance. Suggest avoiding retch and puke. Immuno-Onc far exceeds science. Learn more via ZKSS and the biotech team. 13 1/2 cents per day is the best investmest I have ever made 4 StockGumShoe.com Best2You-Ben
Travis – or anyone – do you think that Biotech Insider Alert actually ‘Alerted’ this recommendation to subscribers today?
All we really know is that the Teaser came out very recently, right?
I’m just wondering because the stock is +20% today on 2.5x volume. (and +5% after hours)
I would think that Subscriber Alerts would be, ordinarily, out of exact sync with Teasers.
Have non-Gumshoes decoded the teaser? Is Gumshoe-dom responsible for (some or much) of the stock blip?
I assume they recommendeded it to their readers well before now, but I don’t know if the ad said anything specific about it — just did a quick “solve” on that one to get it out and didn’t look very closely after that. Certainly lots of people could have “decoded” that one, it’s not a particularly well-hidden secret. And lots of people could have signed up for the newsletter immediately, they’ve got a big mailing list. It does not take much “new” volume to have a dramatic impact on a stock with a market cap this low, particularly if someone’s promising gajillion-percent gains. We could certainly be responsible for some of the blip, my article went live on the site at about 3:15, after the stock had gone up quite a bit, though the email probably didn’t spool to most of our list until the market was closed.
The stock was teased at least once before, prior to when I bought shares of it at $2.32 in Nov 2014. Today’s rise in the stock moved me from being down about 10% to being up about 22% at market’s close, though in May 2015, I was up about 80% from my purchase price. I had bought it at $2.32 after it had come off of a peak of $5.93 in June 2014. TRXC had raised $52.2 million on 1.6 million shares in its IPO on 7 May 2014, and its shares closed that day at $4.32.
There was more buying than selling during the first three months; then it evened out for three months, after which there was more selling than buying, and the stock lost about half its value. At that point, buyers moved in strongly and restored about half the stock’s value by the end of Dec 2014. The stock gradually rose past its IPO valuation around the end of May 2015. At that point, sellers dumped the stock, and it lost 25% of its value, after which it went on a bumpy ride downward, losing another buck/share, until this new show of interest. Sellers are still in the majority, but some apparently see the company as holding more promise now than it has over the past seven months. Or else, it’s just a new crop of suckers who had never seen this particular tease before.
So what is the name of the stock
trxc
$52.2mm on 1.6mm shares? That would be about $32.60/sh. Doesn’t sound right. Had $52mm cash and $19mm debt as of 9/30/15, so $33mm net cash, or about $.33/sh based on 100mm shares. Current burn rate about $9mm/qtr. Burned through $35mm in 2014 and TTM thru 9/30/15. Probably has 4 quarters of cash at this point.
The email leading to presentation and sale of newsletter when out today to members.
It has been out since January 15th when stock was sub $2
I got it today and also a while back. Just looking for new subscribers
If you have a product to sell and it’s use is off the charts, don’t you think this company will rocket, the hospitals will jump on this, the surgeons will answer. Hospitals that can’t afford De Vinci, can afford this and it will pay for itself in one year. The payback is tremendous. Hospitals are cheap. If its FDA approved, get it done. Get our surgeons going and trained. It will make us money. It’s a money maker. It’s got to hit big until TRXC comes out with Suribot 2. With a worldwide market for surgeries, we want to be the leader, not the follower.
This is a good predictive call by Money Map. Since our original coverage of TransEnterix for the Biotech portion of Stock Gumshoe, the pot has sweetened considerably: smart hires, a powerhouse affiliation with an Italian robotics firm, crystallization of plans subsequently to pursue EU approval of Surgibot, insider acquisition of shares. I agree with Travis’s disquisition of the facts and particulars of the company.
Disclosure: I am long $TRXC
Disclosure: I know the founder of $TRXC but have not discussed the company with him. The founder is a serial medical inventor and entrepreneur, honest, competent, credible, and someone I have no hesitation whatsoever investing in. He has made serious money for his prior investors in other medical device ventures.
Thanks for the info!
So you stand behind what everyone every person at your company from Tom Gentile, Mike Ward Publisher of Energy Advantage, Dr Kent Moors, Shah Gilani who have been sending out emails blasts that the opportunity ends tonight ( over a period of a few days). With Mike Ward consistently standing behind this. It seems like the historic announcement is not imminent. Can you clarify because Money Map Press seems to be going overboard here. They didn’t do this with Dr Moore’s solar energy pitch. What is going on?
Dr. KSS does not work for Money Map, he just happened to agree with them and like TRXC (though he wrote about it long before they did).
The promises from Money Map that something would happen on a given day were hogwash, designed to separate subscribers from their money quickly. They know that if they say “in a month or two” in their ads, no one will sign up… if they say “maybe by tomorrow, so you have to sign up by midnight!” then they’ll get many more subscribers.
The stock has been on a wild ride because of speculation and pundit attention leading up to the FDA’s response, which is due sometime in the next month or two but is not predictable to the day. Money Map has been a big part of that because of their huge marketing push about the stock, but it has also been propped up by the acquisition rumor mill — when a stock is propped up by news and rumors, one danger is that it can fall just because of a brief period with no news.
And FDA approval is widely expected, so it’s hard to guess how much that might move the stock — usually stocks move most sharply when the unexpected happens. If the device does get approved, all attention will go to orders and commercial ramp up and talk about actual sales, which will probably be very lumpy if it’s anything like the rollout of intuitive surgical’s Da Vinci.
And I would argue that they did indeed do very similar marketing of Kent Moors’ pitch for solar a couple months ago, though it didn’t drive up the share price as much in that case because SunEdison is a balance sheet disaster that more people are afraid of, and it didn’t have the urgency of an upcoming FDA response date that could fundamentally change the company’s business overnight (good or bad, of course, like all FDA responses). Marketing newsletters based on an upcoming FDA response or anticipated clinical trial results is very common and does tend to be more focused on a specific timeline, since there is a specific catalyst — advertisers love specific dates and catalysts because they can use them to spur subscribers to sign up quickly, so those ads often get more play than others.
thanks
At today’s close, it’s priced at a modest 1300 times sales. Hope the devices work well with heart surgery…it’s investors may be needing it soon.
How can you value a pre-sales Company on a sales multiple? You have to look at the technology and the market size… With your thinking you could never invest in a technology or biotech company pre-sales…
Here is a link to Transenterix’s recent presentation that gives both the caveats regarding their prospects and the selling points of the product that is awaiting FDA approval. Comparing it with some of the other products for which links are provided below might help you make some decisions regarding investing in this one:
http://ir.transenterix.com/events.cfm
Note: I had to provide name, email, and “company,” for which I put “shareholder” and was given access to the slides.
As I said, I don’t know much about this one’s real prospects personally — but this is a pre-sales company in most real senses, they have some products but the hope is that their SurgiBot system, presuming it’s approved in the next couple months, would be transformational in terms of revenue growth. Sell 100 units at $500,000 each in the first year (may not happen, but that’s far from being the optimistic forecast) and they’re trading at 5X sales.
Is anyone familiar with “The Precision Profits System”, a Sovereign Society newsletter.
I received a promotion from them where they state “close out a gain of 100% (or more) … every month”. The promotion, a very long video, states, “Please Note: Since unveiling this system on November 17, we’ve closed out 5 more triple digit winners (104%, 100%, 101%, 207%, and 218%) “.
Cost: one-year membership is a mere $1,495!! Comes with 90 day money back guarantee.
Stock Gumshoe is a much better deal at a mere 13 1/2 CENTS per day $49 annual Irregular membership – Best Investment I ever made 🙂 Best2You-Ben
Amen, Brother Ben. I feel the same.
Go ahead Travis. Take a bow. Don’t be bashful.
Well in only 3 months if they had invested their own money every dollar would be now worth 128. Why do they need 1495 when they have such awesome investments?
Think what that 1 dollar will grow to in ten years. Likely more than all the dollars in the universe.
“What I try to remind myself is that if the prospects are so phenomenal, then this will be a fine investment next year, and the year after that. Why not put off buying the stock until later when the company has established a record? Wait for the earnings. You can get tenbaggers in companies that have already proven themselves. When in doubt, tune in later”. Peter Lynch, One up On Wall Street, Chapter 9, page 159. Stocks i’d Avoid.
A hint to the wise is sufficient
Good advice in many respects — people sometimes find it hard to buy expensive growth stocks, but it can be a lot safer than buying “might grow” stocks before the marketplace has sorted out who the winners will be. Not as much fun, of course, being in early feels fantastic — but often safer.
Intuitive’s Da Vinci Dominates But Google To Challenge:
http://finance.yahoo.com/video/intuitives-da-vinci-dominates-google-154400982.html
Pay particular attention to the first minute or so of the video.
http://www.fiercemedicaldevices.com/story/intuitive-ceo-bats-away-future-robotic-surgery-competitors/2016-01-25
Titan’s Sport ready roll strong in 2016!!!
Go Broncos! Awesome Dude!
what is the company name ..?
Yes, I’d also like to know the name. For a subscription of close to $1500.00, that pays 2 months of my rent. I do not have currently that kind of money hanging around for a subscription that I more than likely will not read through. I don’t have a lot to invest, so money is precious to me. I would like to invest, earn some money and eventually get some bills paid down. I get annoyed when I click on a site like this and then have to listen to an hours worth of someone talking and they keep telling me in just a moment I’m going to …., then in another moment or minute, the same thing. I’m new at investing.
Trish, when you get a video ad like the one in discussion here, just click on the x of the url to close the page and you will be presented with a choice to either stay on the page or leave. Select stay and then the video will disappear and a text content will replace it. You can scroll through it as you wish. the name of the stock is TRXC.
I listened to the entire video, my thoughts exactly!
Trish, it’s TransEnterix, Inc. or ( TRXC)
suren and Trish Transenterix is company name TRXC is symbol. You will find NO newsletter that gives better information than GS. $49.00 a year for irregulars. IMHO
Stockgumshoe 13 1/2 Cents / day… incredible arth1 🙂
So, at what price will who short this one?
Maybe after one more strong run up day?
Give me one more 20% upside day. I am shorting. Might be $20 down the line, but I will risk my personal dollars short term. $1.50 when the orchids come up in the Midwest. After that, buying long at the price when the promotion hit. It’s worked for me. Time after time after time. Thank you Travis. Thank you KSS. Thank you all. Your knowledge humbles me.
Don’t know if you saw it or not but according to “The Street”, word as of today, is that Johnson and Johnson is in the process of mounting a takeover bid. Prior to today, the rapid rise was probably newsletter puffery but if a takeover bid is anywhere imminent then this could prove to be a legitimate catalysts. I hope so anyway, long call options.
Em, I doubt that will happen. Well you never know, but at this time that just seems to be a rumor. For them to do that they would in effect be chucking in the towel on their partnership with Google, and new co. they started (Verb) I think to create new system of their own.
THANK YOU!!! I’ll be buying a TON of these TRXC! My stocks are steady going. WRMT, CHGI, STM, MDT… the 4th industrial revolution is coming and I’ll be ready.
Lions and Tigers and Bears… oh my, shorts in trouble, this new tease is just hitting inboxes today.
Mike Ward here with a breaking alert…
A bidding war is heating up, and you need to move fast.
At this moment, sources show that Johnson & Johnson (the $50 billion medical device giant), and Google (the $300 billion technology titan) are both plotting takeover bids for a tiny $2 microcap.
Although this company is small – a mere $300 million market cap – they hold critical patents that could forever transform the medical landscape. In fact, they are awaiting an imminent FDA decision that could immediately impact 27 million Americans and unlock an expected $18 billion market.
In addition, this company is part of a unique market sector responsible for rare and exceptional trades big enough to turn $1,000 into $1.6 million.
If the rumors are true, a bidding war between JNJ and Google could drive this tiny $2 stock into the stratosphere and beyond.
Already, institutions and insiders closest to the action have grabbed up 96% of the available shares in advance of a possible takeover battle.
Trading volume just surged a staggering 2,500% in a single day…
Time is of the essence…
Hey guys, newbie trader here. If I was to purchase shares in TRXC what would be a reasonable trail stop %? Also, what would be a modest prediction $$ amount you foresee in the next couple months?
Andrew, Just my humble opinion, but I believe that TRXC should be bought and held for a long time. They are just getting started in what could be a very big field of
robotic surgery. The numbers are staggering going forward. Now about 2 billion a year. Projected to be around 10 Billion a year in 4-5 years.
TRXC has great management, hopefully the machine is good. From what I can dig up the reception from Surgeons has been pretty good.
Not many players so TRXC just has to capture say 5% of market share. Sheesh that’s nothing to bring in revs of 500 mil.
Do your on D&D, but like I said I think this one you hold on for the ride.
Am am loaded for bear on this, and staying long till the cows come home.
Hope I’m right.
Has anybody found any comments from Google or J&Johnson that they are bidding or in discussions to buy this company? Or is all buyout/ bidding war info from Money Map Press?
If it’s all from the crew at Money Map (and true)…..wouldn’t that be insider knowledge?….(if it’s all false)….couldn’t that be a lawsuit?
I’m all twisted up so I’m staying on the sidelines for now.
This is typical of Money Map Press. They pump a stock touting the potential for immediate outrageous gains, the stock climbs significantly for a few days following the rec, and then it falls. There’s probably a short play in there, but I’m not a gambler.
Today’s price action is a case in point.
U r right, typical Money Map Press. TRXC up one day and now heading south. These people’s only winner was ATVI and if u didn’t dump it recently it is outta here heading south. They continually hype stocks and never come up with a winner..FL, EAR, EA etc. Why Stuart Varney uses Fitzgerald as a stock guru is beyond me. He never picks a winner, well maybe one out of 10 but anyone can do better by randomly picking.
I also agree about all the BS hype, ridiculous. I think this one might have some legs, got in at 2.60 knowing it may drop. It’s now close enough to FDA approval to take a stab at it, should have a decent read on it in 6 months. These types of stocks can spike in a hurry on news and I don’t think the downside risk is to bad. Travis got this one out quick but I caught it 5 minutes too late to get in that day. Paid a big premium in the morning. Long term play or a buy out, it’s got potential, even without the extra hype. Hopefully it’s 1 of the 10……
Yes can you help a poor inverter out and tell me the name of the stock I don’t have 2 grand.
Mark
I heard about The J and J connection on The Street. Also that MoneyMap guy kind of got the back story wrong I think. Not so long ago, few months I think, Google and J/J entered into some kind of agreement to develope Robotic Surgical endeavor. Came across this in a couple different places while net surfing. Thus while J/J may very well be interested but as Google’s partner and not their competitor. It would be nice if someone else were to jump in and compete but my understanding is it won’t be Google. Hope this helps a little.
I would say to the doctor who know the owner of TRXC, don’t sell for less then $10,000 a share. J&J would kick in $5000 a share. Google would kick in $5000 a share. I guess the Calpers and other pension funds can’t buy in until this becomes a $5 stock. Then, it might be too late for them. Who know. Shoot for the moon!!
That would be the day 🙂
Thanks as always Travis, your site is the best on the internet. I bought a similar medical device company EDAP that specializes in Robotic Ultrasound (HIFU) as a means to treat prostate cancer. It obtained FDA approval in late 2015 and is now in marketing and distribution phase for the U.S. . They are also part of research consortium with GE for a liver cancer. One thing that I learned about medical device companies is some take awhile to become known and accepted by the medical community, but if the technology is there, you could be looking at 10-20 baggers. I think I might dip a little into TRXC, thanks. Take a look at EDAP, low float, cash flow neutral, no analysts covering (yet) and no hype.
EDAP-Thank you Timothy for the heads up 🙂 and welcome to the Gummune!
http://www.edap-tms.com/ Best2You-Ben
Thanks Timothy, looks interesting. And I agree about your comments about this site.
First day as a free member. Reading all these post of great information makes me feel like I now have an edge!! I been surfing around the web for this stock for awhile. Thanks all! Day one and I belive this site will be my go to for honest reports with no hype mambo jumbo.
Will be purchasing my subscription shortly!
Welcome to Stock Gumshoe riskfactor 🙂 Best2you-Ben
Does anybody have the biopic surgeon stock symbol?
TRXC.A
In regards to the buyout/bidding rumor news:
Money Map released that the two companies may start a bidding war….then, the street released a PR that per Money Map, rumors of a buyout (that included Money Map in the headline). Next, Money Map releases that it’s a fact that buyout rumors are swirling through the market.
That’s a full circle that started with money map and now the money map group is acting like it started elsewhere. ??
Our Feature this week is a Q&A with Amir Ronen, CEO of closely-held Sensible Medical Innovations, who discusses the company’s ReDS technology and a wearable vest to measure lung fluid content for managing heart failure patients.
Of special interest in our Briefs section was Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) entering into an agreement giving Knight exclusive rights to commercialize Titan’s Probuphine in Canada; TearLab (NASDAQ:TEAR; TSX:TLB) reporting on its business outlook, a proposed financing and an estimated increase in fourth quarter revenue of about 28%; Dipexium Pharmaceuticals (NASDAQ:DPRX) receiving new Locilex patents in Australia and New Zealand; Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) posting results of a Phase 2 study of drug candidate, TT401, for the treatment of Type 2 diabetes; Venaxis (NASDAQ:APPY) agreeing to merge with India’s Strand Life Sciences; and Avivagen (TSX-V:VIV) starting a broiler poultry trial with OxC-beta in Spain.
In Wall Street news, Rodman initiated coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG), BioBlast Pharma (NASDAQ:ORPN) and VolitionRx (NASDAQ:VNRX) at “buy’ with 12-month price targets of $10, $25 and $12, respectively. Also, Leerink Partners downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” and reduced its price target to $1.83 from $15 after the company reported results from its COR 1.1 trial. Your friends at BioTuesdays.com.